Brian D Kavanagh

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11099946/publications.pdf

Version: 2024-02-01

129	11,156	57758 44	30087 103
papers	citations	h-index	g-index

129	129	129	9174
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Nonâ€“Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. Journal of Clinical Oncology, 2019, 37, 1558-1565.	1.6	882
2	Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncology, The, 2016, 17, 1672-1682.	10.7	865
3	Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Liver Metastases. Journal of Clinical Oncology, 2009, 27, 1572-1578.	1.6	753
4	Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Lung Metastases. Journal of Clinical Oncology, 2009, 27, 1579-1584.	1.6	729
5	Radiation-Associated Liver Injury. International Journal of Radiation Oncology Biology Physics, 2010, 76, S94-S100.	0.8	592
6	Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1807-1814.	1.1	585
7	Stereotactic Body Radiation Therapy in Multiple Organ Sites. Journal of Clinical Oncology, 2007, 25, 947-952.	1.6	401
8	A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. International Journal of Radiation Oncology Biology Physics, 2005, 62, 1371-1378.	0.8	384
9	Management of Brain Metastases in Tyrosine Kinase Inhibitorâ€“NaÃ¯ve Epidermal Growth Factor Receptorâ€“Mutant Nonâ€“Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis. Journal of Clinical Oncology, 2017, 35, 1070-1077.	1.6	372
10	Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Nonâ€“Small-Cell Lung Cancer and Brain Metastasis. Journal of Clinical Oncology, 2016, 34, 123-129.	1.6	284
11	Stereotactic body radiotherapy for colorectal liver metastases. Cancer, 2011, 117, 4060-4069.	4.1	265
12	Chest Wall Volume Receiving >30 Gy Predicts Risk of Severe Pain and/or Rib Fracture After Lung Stereotactic Body Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2010, 76, 796-801.	0.8	261
13	Phase II Trial of Stereotactic Body Radiation Therapy Combined With Erlotinib for Patients With Limited but Progressive Metastatic Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2014, 32, 3824-3830.	1.6	244
14	Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer. Journal of Clinical Oncology, 2016, 34, 2835-2842.	1.6	213
15	Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta OncolÃ³gica, 2006, 45, 848-855.	1.8	188
16	Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients Receiving Crizotinib. International Journal of Radiation Oncology Biology Physics, 2014, 88, 892-898.	0.8	182
17	Predictors of Rectal Tolerance Observed in a Dose-Escalated Phase 1-2 Trial of Stereotactic Body Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 89, 509-517.	0.8	177
18	Hepatic Radiation Toxicity: Avoidance and Amelioration. Seminars in Radiation Oncology, 2011, 21, 256-263.	2.2	176

#	Article	IF	Citations
19	Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement. Radiotherapy and Oncology, 2020, 146, 223-229.	0.6	168
20	Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. Acta OncolÃ³gica, 2009, 48, 578-583.	1.8	153
21	Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiation Oncology, 2011, 6, 34.	2.7	137
22	Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 Studies. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1357-1366.	0.8	134
23	Extracranial Radiosurgery (Stereotactic Body Radiation Therapy) for Oligometastases. Seminars in Radiation Oncology, 2006, 16, 77-84.	2.2	125
24	The North American Experience with Stereotactic Body Radiation Therapy in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2007, 2, S101-S112.	1.1	124
25	Stereotactic body radiation therapy for low and intermediate risk prostate cancerâ€"Results from a multi-institutional clinical trial. European Journal of Cancer, 2016, 59, 142-151.	2.8	124
26	Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases. JAMA Oncology, 2020, 6, 1028.	7.1	122
27	Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 105, 346-355.	0.8	115
28	Post-Treatment Mortality After Surgery and Stereotactic Body Radiotherapy for Early-Stage Nonâ€"Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 642-651.	1.6	111
29	The Impact of Definitive Local Therapy for Lymph Node-Positive Prostate Cancer: A Population-Based Study. International Journal of Radiation Oncology Biology Physics, 2014, 88, 1064-1073.	0.8	94
30	The Impact of Postoperative Radiotherapy for Thymoma and Thymic Carcinoma. Journal of Thoracic Oncology, 2017, 12, 734-744.	1.1	94
31	Recurrent Cervical Carcinoma: Typical and Atypical Manifestations. Radiographics, 1999, 19, S103-S116.	3.3	84
32	Phase II Trial of Hypofractionated IMRT With Temozolomide for Patients With Newly Diagnosed Glioblastoma Multiforme. International Journal of Radiation Oncology Biology Physics, 2012, 84, 655-660.	0.8	72
33	A Phase I Dose-Escalation Study of Fractionated Stereotactic Radiosurgery in Combination With Gefitinib in Patients With Recurrent Malignant Gliomas. International Journal of Radiation Oncology Biology Physics, 2008, 70, 993-1001.	0.8	65
34	Calcium-Dependent Stimulation of Mitogen-Activated Protein Kinase Activity in A431 Cells by Low Doses of Ionizing Radiation. Radiation Research, 1998, 149, 579.	1.5	63
35	Stereotactic Body Radiation Therapy. Current Problems in Cancer, 2005, 29, 120-157.	2.0	63
36	Clinical application of intensity-modulated radiotherapy for locally advanced cervical cancer. Seminars in Radiation Oncology, 2002, 12, 260-271.	2.2	60

#	Article	IF	Citations
37	High Dose per Fraction, Hypofractionated Treatment Effects in the Clinic (HyTEC): An Overview. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1-10.	0.8	60
38	Clinical Validation of 4-Dimensional Computed Tomography Ventilation With Pulmonary Function Test Data. International Journal of Radiation Oncology Biology Physics, 2015, 92, 423-429.	0.8	59
39	Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant?. Practical Radiation Oncology, 2015, 5, e589-e596.	2.1	59
40	Stereotactic ablative radiotherapy: what's in a name?. Practical Radiation Oncology, 2011, 1, 38-39.	2.1	53
41	Comparison of 4-Dimensional Computed Tomography Ventilation With Nuclear Medicine Ventilation-Perfusion Imaging: A Clinical Validation Study. International Journal of Radiation Oncology Biology Physics, 2014, 89, 199-205.	0.8	50
42	The prognostic significance of Gleason scores in metastatic prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 707-713.	1.6	48
43	Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to Thoracic, Abdominal, and Soft Tissue Lesions Using Stereotactic Body Radiotherapy (SBRT). Radiation Oncology, 2015, 10, 218.	2.7	48
44	Prophylactic Cranial Irradiation (PCI) versus Active MRI Surveillance for Small Cell Lung Cancer: The Case for Equipoise. Journal of Thoracic Oncology, 2017, 12, 1746-1754.	1.1	48
45	Excellent Outcomes with Radiosurgery for MultipleÂBrain Metastases in ALK and EGFR DrivenÂNonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 715-720.	1.1	48
46	Radiosurgery alone is associated with favorable outcomes for brain metastases from small-cell lung cancer. Lung Cancer, 2018, 120, 88-90.	2.0	47
47	Phase I Trial of Hypofractionated Intensity-Modulated Radiotherapy With Temozolomide Chemotherapy for Patients With Newly Diagnosed Glioblastoma Multiforme. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1066-1074.	0.8	46
48	Combined-Modality Therapy With Radiation and Chemotherapy for Elderly Patients With Glioblastoma in the Temozolomide Era. JAMA Neurology, 2016, 73, 821.	9.0	46
49	Combination of Trastuzumab Emtansine and Stereotactic Radiosurgery Results in High Rates of Clinically Significant Radionecrosis and Dysregulation of Aquaporin-4. Clinical Cancer Research, 2019, 25, 3946-3953.	7.0	46
50	Determining the optimal block margin on the planning target volume for extracranial stereotactic radiotherapy. International Journal of Radiation Oncology Biology Physics, 1999, 45, 515-520.	0.8	43
51	Radiation Therapy for Liver Metastases. Seminars in Radiation Oncology, 2011, 21, 264-270.	2.2	40
52	Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic: An ESTRO-ASTRO Consensus Statement. International Journal of Radiation Oncology Biology Physics, 2020, 107, 631-640.	0.8	40
53	Favorable Prognosis in Patients With High-Grade Glioma With Radiation Necrosis: The University of Colorado Reoperation Series. International Journal of Radiation Oncology Biology Physics, 2011, 81, 211-217.	0.8	37
54	Inception of a national multidisciplinary registry for stereotactic radiosurgery. Journal of Neurosurgery, 2016, 124, 155-162.	1.6	37

#	Article	IF	Citations
55	Survival Outcomes of Whole-Pelvic Versus Prostate-Only Radiation Therapy for High-Risk Prostate Cancer Patients With Use of the National Cancer Data Base. International Journal of Radiation Oncology Biology Physics, 2015, 93, 1052-1063.	0.8	32
56	National trends in radiotherapy for brain metastases at time of diagnosis of non-small cell lung cancer. Journal of Clinical Neuroscience, 2017, 45, 48-53.	1.5	32
57	Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide. Journal of Neuro-Oncology, 2013, 114, 111-116.	2.9	30
58	Fluorodeoxyglucose Positron Emission Tomography Response and Normal Tissue Regeneration After Stereotactic Body Radiotherapy to Liver Metastases. International Journal of Radiation Oncology Biology Physics, 2012, 83, e613-e618.	0.8	29
59	Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma. Journal of Neuro-Oncology, 2015, 122, 135-143.	2.9	29
60	No Longer a Match: Trends in Radiation Oncology National Resident Matching Program (NRMP) Data from 2010-2020 and Comparison Across Specialties. International Journal of Radiation Oncology Biology Physics, 2021, 110, 278-287.	0.8	29
61	A theoretical model for the effects of reduced hemoglobin-oxygen affinity on tumor oxygenation. International Journal of Radiation Oncology Biology Physics, 2002, 53, 172-179.	0.8	28
62	Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy: An Overview of Technical Considerations and Clinical Applications. Hematology/Oncology Clinics of North America, 2006, 20, 87-95.	2.2	27
63	Advances in Treatment Techniques. Cancer Journal (Sudbury, Mass), 2011, 17, 177-181.	2.0	27
64	Gleason stratifications prognostic for survival in men receiving definitive external beam radiation therapy for localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 71.e11-71.e19.	1.6	27
65	Syndrome of inappropriate secretion of antidiuretic hormone in a patient with carcinoma of the nasopharynx. Cancer, 1992, 69, 1315-1319.	4.1	26
66	A pilot study of concomitant boost accelerated superfractionated radiotherapy for stage III cancer of the uterine cervix. International Journal of Radiation Oncology Biology Physics, 1997, 38, 561-568.	0.8	26
67	A phase I/II trial of stereotactic body radiation therapy (SBRT) for lung metastases: Initial report of dose escalation and early toxicity. International Journal of Radiation Oncology Biology Physics, 2006, 66, S120-S127.	0.8	26
68	Technical considerations in the application of intensity-modulated radiotherapy as a concomitant integrated boost for locally-advanced cervix cancer. Medical Dosimetry, 2002, 27, 177-184.	0.9	25
69	Stereotactic Body Radiotherapy for Liver Metastases. Seminars in Radiation Oncology, 2017, 27, 240-246.	2.2	25
70	Immune checkpoint inhibitors and radiosurgery for newly diagnosed melanoma brain metastases. Journal of Neuro-Oncology, 2018, 140, 55-62.	2.9	25
71	The Impact of Adjuvant Radiation Therapy for High-Grade Gliomas by Histology in the United States Population. International Journal of Radiation Oncology Biology Physics, 2014, 90, 894-902.	0.8	23
72	Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials. Journal of Neuro-Oncology, 2015, 123, 251-257.	2.9	22

#	Article	IF	Citations
73	How Will Big Data Impact Clinical Decision Making and Precision Medicine in Radiation Therapy?. International Journal of Radiation Oncology Biology Physics, 2016, 95, 880-884.	0.8	22
74	Survival Outcomes of Dose-Escalated External Beam Radiotherapy versus Combined Brachytherapy for Intermediate and High Risk Prostate Cancer Using the National Cancer Data Base. Journal of Urology, 2016, 195, 1453-1458.	0.4	22
75	Normal Liver Tissue Density Dose Response in Patients Treated With Stereotactic Body Radiation Therapy for Liver Metastases. International Journal of Radiation Oncology Biology Physics, 2012, 84, e441-e446.	0.8	21
76	Radiographic and Histopathologic Observations After Combined EGFR Inhibition and Hypofractionated Stereotactic Radiosurgery in Patients With Recurrent Malignant Gliomas. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1352-1357.	0.8	16
77	Comparison of Radiation-Induced Normal Lung Tissue Density Changes for Patients From Multiple Institutions Receiving Conventional or Hypofractionated Treatments. International Journal of Radiation Oncology Biology Physics, 2014, 89, 626-632.	0.8	16
78	The dosimetric effect of inhomogeneity correction in dynamic conformal arc stereotactic body radiation therapy for lung tumors. Journal of Applied Clinical Medical Physics, 2006, 7, 58-63.	1.9	14
79	Liver, Renal, and Retroperitoneal Tumors: Stereotactic Radiotherapy. , 2007, 40, 415-426.		14
80	Highâ€dose MVCT image guidance for stereotactic body radiation therapy. Medical Physics, 2012, 39, 4812-4819.	3.0	14
81	The Expanding Roles of Stereotactic Body Radiation Therapy and Oligofractionation: Toward a New Practice of Radiotherapy. Frontiers of Radiation Therapy and Oncology, 2011, 43, 370-381.	1.4	13
82	Survival benefit of postoperative radiation in papillary meningioma: Analysis of the National Cancer Data Base. Reports of Practical Oncology and Radiotherapy, 2017, 22, 495-501.	0.6	13
83	External Validation of the Benefit of Adjuvant Radiotherapy for Pathologic N1M0 Prostate Cancer. Journal of Clinical Oncology, 2015, 33, 1987-1988.	1.6	12
84	Survival outcomes of radiotherapy with or without androgen-deprivation therapy for patients with intermediate-risk prostate cancer using the National Cancer Data Base. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 165.e1-165.e9.	1.6	12
85	Hypofractionated intensityâ€modulated radiotherapy with temozolomide chemotherapy may alter the patterns of failure in patients with glioblastoma multiforme. Journal of Medical Imaging and Radiation Oncology, 2014, 58, 714-721.	1.8	11
86	The Head Start Effect: Will Acute and Delayed Postoperative Mortality Lead to Improved Survival with Stereotactic Body Radiation Therapy for Operable Stage I Nonâ€“Small-Cell Lung Cancer?. Journal of Clinical Oncology, 2017, 35, 1749-1751.	1.6	11
87	Central Nervous System Response to Selpercartinib in Patient With RET-rearranged Non-small Cell Lung Cancer After Developing Leptomeningeal Disease on Pralsetinib. Clinical Lung Cancer, 2022, 23, e5-e8.	2.6	11
88	Soft tissue complication rates after low dose rate brachytherapy using customized perineal templates. International Journal of Radiation Oncology Biology Physics, 1994, 30, 508.	0.8	9
89	Long-term Local Control and Survival After Concomitant Boost Accelerated Radiotherapy for Locally Advanced Cervix Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2001, 24, 113-119.	1.3	9
90	Stereotactic Body Radiation Therapy As a Derivative of Stereotactic Radiosurgery: Clinically Independent But With Enduring Common Themes. Journal of Clinical Oncology, 2014, 32, 2827-2831.	1.6	8

#	Article	IF	Citations
91	Stereotactic body radiation therapy (SBRT) for liver metastases: A clinical review. Seminars in Colon and Rectal Surgery, 2014, 25, 48-52.	0.3	8
92	Survival outcomes of combined external beam radiotherapy and brachytherapy vs. brachytherapy alone for intermediate-risk prostate cancer patients using the National Cancer Data Base. Brachytherapy, 2016, 15, 136-146.	0.5	8
93	Medical operability and inoperability drive survival in retrospective analyses comparing surgery and SBRT for early-stage lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 810-811.	0.8	8
94	Improved survival with stereotactic ablative radiotherapy (SABR) over lobectomy for early stage non-small cell lung cancer (NSCLC): addressing the fallout of disruptive randomized data. Annals of Translational Medicine, 2015, 3, 149.	1.7	8
95	Radiation Oncologist Concerns About Increased Electronic Brachytherapy Use for Skin Cancer. JAMA Dermatology, 2015, 151, 1036.	4.1	7
96	Prostate Cancer Central Nervous System Metastasis in a Contemporary Cohort. Clinical Genitourinary Cancer, 2021, 19, 217-222.e1.	1.9	7
97	Improved Cosmesis in Early Breast Cancer Using Conformal Radiotherapy. Journal of Clinical Oncology, 2013, 31, 4483-4484.	1.6	6
98	Radiation Oncology: A Snapshot in Time, 2014. Journal of Clinical Oncology, 2014, 32, 2825-2826.	1.6	6
99	Prophylactic cranial irradiation in small-cell lung cancer. Lancet Oncology, The, 2017, 18, e365.	10.7	5
100	Radiation Oncology: A Perspective on Health Reform and Value-Based Initiatives. Journal of Oncology Practice, 2014, 10, e212-e214.	2.5	4
101	Factors associated with progression and mortality among patients undergoing stereotactic radiosurgery for intracranial metastasis: results from a national real-world registry. Journal of Neurosurgery, 2022, 137, 985-998.	1.6	4
102	Gynecologic Brachytherapy: Digital Fluoroscopy for Placement Verification and Treatment Planning. Radiology, 2000, 215, 900-903.	7.3	3
103	The emperor's new isodose curves. Medical Physics, 2003, 30, 2559-2560.	3.0	3
104	Stereotactic Body Radiation Therapy: A New Paradigm in Radiotherapy Management of Cancer. Journal of the American College of Radiology, 2008, 5, 673-677.	1.8	3
105	Reply to X. Mirabel. Journal of Clinical Oncology, 2009, 27, e41-e41.	1.6	3
106	Long-term results of combined modality therapy for esophageal cancer. Radiation Oncology Investigations, 1993, 1, 227-234.	0.9	2
107	Clinical use of a digital simulator for rapid setup verification in high dose rate brachytherapy. International Journal of Radiation Oncology Biology Physics, 1995, 33, 931-936.	0.8	2
108	Outcomes of symptomatic compared to asymptomatic recurrences in patients with glioblastoma multiforme (GBM). Journal of Radiation Oncology, 2016, 5, 33-39.	0.7	2

#	Article	IF	Citations
109	Tracing the earliest medical uses of high dose-per-fraction external beam radiation. Journal of Radiosurgery and SBRT, 2011, 1, 5-11.	0.2	2
110	Radiation Therapy for Head and Neck Cancer in a Patient with Takayasu's Arteritis. Acta OncolÃ³gica, 1994, 33, 73-74.	1.8	1
111	In response to Deore et al.. International Journal of Radiation Oncology Biology Physics, 1995, 32, 556.	0.8	1
112	Presumed early-stage lung cancer treated with stereotactic body radiation therapy in a medically inoperable patient with multiple connective tissue disorders. Practical Radiation Oncology, 2012, 2, e133-e136.	2.1	1
113	In Regard to Jagsi etÂal. International Journal of Radiation Oncology Biology Physics, 2015, 91, 679-680.	0.8	1
114	Stereotactic Body Irradiation. , 2016, , 427-431.e1.		1
115	Halfway Toward Half Full. International Journal of Radiation Oncology Biology Physics, 2019, 104, 997-998.	0.8	1
116	Model Insurance Coverage Policies: The Power of Suggestion, the Force of Evidence. International Journal of Radiation Oncology Biology Physics, 2019, 104, 745-747.	0.8	1
117	The Virtual Visiting Professor: A Step Toward a Parasocial Common Curriculum?. International Journal of Radiation Oncology Biology Physics, 2020, 108, 466-469.	0.8	1
118	The HyTEC Project. Medical Physics, 2021, 48, 2699-2700.	3.0	1
119	The Economics of Using Locally Ablative Therapy in Oligometastatic Cancer. Seminars in Radiation Oncology, 2021, 31, 250-252.	2.2	1
120	Navigating Past the Chaos of the Radiation Oncology 2021 Match. International Journal of Radiation Oncology Biology Physics, 2021, 111, 328-330.	0.8	1
121	Stereotactic Irradiation. , 2016, , 419-426.e2.		1
122	Improved survival with the addition of radiotherapy to androgen deprivation: questions answered and a review of current controversies in radiotherapy for non-metastatic prostate cancer. Annals of Translational Medicine, 2016, 4, 14.	1.7	1
123	Syndrome of inappropriate secretion of antidiuretic hormone in a patient with carcinoma of the nasopharynx. Cancer, 1993, 72, 299-299.	4.1	0
124	Physicists who are responsible for highâ€tech radiotherapy procedures should have to be specially credentialed. Medical Physics, 2012, 39, 7181-7184.	3.0	0
125	Efficacy of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to the prostate for intermediate- and high-risk prostate cancer. Journal of Radiation Oncology, 2014, 3, 401-407.	0.7	0
126	From the Guest Editor. Cancer Journal (Sudbury, Mass), 2016, 22, 245-246.	2.0	0

#	Article	IF	Citations
127	Reply to J.B. Aragon-Ching and D. Dalela et al. Journal of Clinical Oncology, 2017, 35, 916-917.	1.6	0
128	Honor Was Never Lost: The National Farm Machinery Show and the American Society for Radiation Oncology Annual Meeting. International Journal of Radiation Oncology Biology Physics, 2018, 101, 259-260.	0.8	0
129	Back to the future: a proton pro/con. Oncology, 2011, 25, 657, 660, 662-3.	0.5	0